Sufferers of early-onset Alzheimer’s could be one step closer to being offered a drug to slow down the progress of the disease.<br /><br /> Lilly pharmaceutical company has released data suggesting its Solanezumab drug can cut the rate of progression by around 34 percent in the early stages.<br /><br /> The findings were presented by the University of Southern California’s Paul Aisen at the Alzheimer’s Association International Conference.<br /><br /> “It suggests that starting therapy early is important. That you will be modifying the underlying disease in a way that accrues benefit with time, so that the earlier you start, the greater the benefit and if you start therapy later, you don’t catch up.” <br /><br /> Worldwide, almost 44 million people have Alzheimer’s or a related form of dementia.<br /><br /> Current medication helps the dying brain cells to function, but it is hoped the new drug will go one step further and help keep them alive.<br /><br /> However experts are warning people to manage their expectations. Results due next year fr
